![](/img/cover-not-exists.png)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Schachter, Jacob, Ribas, Antoni, Long, Georgina V, Arance, Ana, Grob, Jean-Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S, McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, NeynLanguage:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)31601-X
Date:
August, 2017
File:
PDF, 945 KB
english, 2017